CAD 0.2
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 39.86 Thousand CAD | 255.75% |
2022 | 11.2 Thousand CAD | -85.83% |
2021 | 79.08 Thousand CAD | 103.79% |
2020 | 38.8 Thousand CAD | 1880.0% |
2019 | 1960.00 CAD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 44.1 Thousand CAD | 10.63% |
2023 Q3 | 29.94 Thousand CAD | 35.08% |
2023 Q1 | 21.6 Thousand CAD | 92.79% |
2023 Q2 | 22.16 Thousand CAD | 2.58% |
2023 Q4 | 39.86 Thousand CAD | 33.16% |
2022 FY | 11.2 Thousand CAD | -85.83% |
2022 Q4 | 11.2 Thousand CAD | 25.68% |
2022 Q3 | 8917.00 CAD | 3.73% |
2022 Q2 | 8596.00 CAD | -82.25% |
2022 Q1 | 48.41 Thousand CAD | -38.78% |
2021 Q4 | 79.08 Thousand CAD | -2.37% |
2021 Q2 | 102.59 Thousand CAD | -17.82% |
2021 FY | 79.08 Thousand CAD | 103.79% |
2021 Q1 | 124.83 Thousand CAD | 0.0% |
2021 Q3 | 81 Thousand CAD | -21.04% |
2020 Q2 | 5000.00 CAD | 0.0% |
2020 FY | 38.8 Thousand CAD | 1880.0% |
2019 FY | 1960.00 CAD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Algernon Pharmaceuticals Inc. | 2.71 Million CAD | 98.534% |
Asep Medical Holdings Inc | 3.05 Million CAD | 98.694% |
BetterLife Pharma Inc. | 8.02 Million CAD | 99.503% |
BioVaxys Technology Corp. | 3.48 Million CAD | 98.856% |
ChitogenX Inc. | 6.71 Million CAD | 99.406% |
Rapid Dose Therapeutics Corp. | 5.04 Million CAD | 99.209% |
Defence Therapeutics Inc. | 4.06 Million CAD | 99.018% |
Entheon Biomedical Corp. | 85.32 Thousand CAD | 53.275% |
Gemina Laboratories Ltd. | 3.04 Million CAD | 98.689% |
Glow Lifetech Corp. | 2.34 Million CAD | 98.301% |
Pharmala Biotech Holdings Inc. | 1.02 Million CAD | 96.126% |
Doseology Sciences Inc. | 82.49 Thousand CAD | 51.669% |
MYND Life Sciences Inc. | 5.77 Million CAD | 99.31% |
Nova Mentis Life Science Corp. | 841.66 Thousand CAD | 95.263% |
PharmaTher Holdings Ltd. | 252.9 Thousand CAD | 84.235% |
PreveCeutical Medical Inc. | 5.95 Million CAD | 99.331% |
Telescope Innovations Corp. | 1.35 Million CAD | 97.049% |